- Home
- CDIO vs KZIA Comparison
CDIO vs KZIA Comparison
Compare CDIO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDIO
- KZIA
- Stock Information
- Founded
- CDIO 2017
- KZIA 1994
- Country
- CDIO United States
- KZIA Australia
- Employees
- CDIO N/A
- KZIA N/A
- Industry
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CDIO Health Care
- KZIA Health Care
- Exchange
- CDIO Nasdaq
- KZIA Nasdaq
- Market Cap
- CDIO 8.0M
- KZIA 9.0M
- IPO Year
- CDIO N/A
- KZIA 1999
- Fundamental
- Price
- CDIO $4.23
- KZIA $7.04
- Analyst Decision
- CDIO
- KZIA Strong Buy
- Analyst Count
- CDIO 0
- KZIA 3
- Target Price
- CDIO N/A
- KZIA $16.00
- AVG Volume (30 Days)
- CDIO 47.5K
- KZIA 187.7K
- Earning Date
- CDIO 11-12-2025
- KZIA 11-14-2025
- Dividend Yield
- CDIO N/A
- KZIA N/A
- EPS Growth
- CDIO N/A
- KZIA N/A
- EPS
- CDIO N/A
- KZIA N/A
- Revenue
- CDIO $19,507.00
- KZIA $1,549,158.00
- Revenue This Year
- CDIO $1,434.82
- KZIA N/A
- Revenue Next Year
- CDIO $4,661.91
- KZIA $49.25
- P/E Ratio
- CDIO N/A
- KZIA N/A
- Revenue Growth
- CDIO N/A
- KZIA 248983.08
- 52 Week Low
- CDIO $3.22
- KZIA $2.86
- 52 Week High
- CDIO $53.10
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- CDIO 50.58
- KZIA 44.03
- Support Level
- CDIO $4.03
- KZIA $6.79
- Resistance Level
- CDIO $4.66
- KZIA $7.29
- Average True Range (ATR)
- CDIO 0.35
- KZIA 0.45
- MACD
- CDIO -0.01
- KZIA 0.03
- Stochastic Oscillator
- CDIO 40.38
- KZIA 42.78
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.